Intramolecular Immunoassay for Probing Paracrine Signaling
用于探测旁分泌信号传导的分子内免疫分析
基本信息
- 批准号:8001695
- 负责人:
- 金额:$ 25.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-09-01 至 2012-08-31
- 项目状态:已结题
- 来源:
- 关键词:Amino AcidsAntibodiesAntigen-Antibody ComplexAntineoplastic AgentsArchitectureBenchmarkingBindingBiological AssayBiological ModelsCell modelCell physiologyCellsCellular AssayClinical TrialsComplexCysteineDetectionDiffuseDiffusionElementsEngineeringEnvironmentEpithelial CellsEpitopesEventExtracellular MatrixFab ImmunoglobulinsFibrinogenFigs - dietaryFluorescenceFluorescence Resonance Energy TransferImageImmunoassayImmunoglobulin GIndividualLabelLengthMethodsMicroscopicModelingModificationMonoclonal AntibodiesNon-Invasive Cancer DetectionParacrine CommunicationPeptidesPhaseProtein IsoformsReaderReagentReporterResolutionRoleScreening procedureSeriesSignal TransductionSignaling MoleculeSiteSolidStructureTestingTimeTissuesTracerTumor BiologyVascular Endothelial Growth Factorsantigen bindingbasecell typedrug discoveryenzyme substrateflexibilityhuman VEGF proteinin vitro Assayinstrumentintercellular communicationmeetingsmonolayernovelpolypeptidepreventprototypepublic health relevancesuccesstooltumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Key elements of tumorigenesis are driven by paracrine signaling between stromal and epithelial cells within the context of the extracellular matrix. Unfortunately, the cellular assays used for drug discovery typically rely on a single cell type grown as a monolayer, and this aspect of tumor biology very poorly. This may be one factor contributing to the low success rate of anti-cancer drugs in clinical trials. Though cellular models incorporating multiple cell types in a tissue-like environment are available, they are difficult to integrate with current automated microscopic imaging platforms used by pharma for high content analysis of cell function. An especially challenging problem is detection of soluble paracrine signaling factors in extracellular matrix. Though antibodies are available for many of these factors, existing immunoassay methods are not suited for use in a dense matrix. A fundamental limitation is the requirement for multiple components: the primary antibody and secondary reporter reagents. To overcome this limitation we are proposing to develop an intramolecular immunoassay; i.e., an antibody with a built-in fluorescent reporter. We will achieve this by tethering a fluorescent tracer on a flexible polypeptide linker to IgG and Fab fragments engineered with seleno cysteine residues for site specific modification. A well characterized monoclonal antibody for vascular endothelial growth factor (VEGF) will be used as an initial model. A series of prototype intramolecular immunoassay reagents will be assembled and tested for fluorescence based detection of VEGF to arrive at the optimal structure. In Phase II, the intramolecular immunoassay will be combined with BellBrook's novel microconduit array platform, iuvo, to enable dynamic imaging of paracrine signaling at the level of soluble factors secreted from individual cells.
PUBLIC HEALTH RELEVANCE:
Important aspects of tumorigenesis are controlled by signaling between different cell types that reside in a dense matrix that provides structural support to tissues and also participates in signaling. Unfortunately, it is very difficult to incorporate these signaling events into in vitro assays that can be used to test potential anti-cancer drugs. To overcome this limitation, we propose to develop a novel immunoassay method that would allow probing of cell-cell signaling in a tissue-like matrix using existing automated detection instruments.
描述(由申请人提供):肿瘤发生的关键要素是由细胞外基质内的基质细胞和上皮细胞之间的旁分泌信号传导驱动的。不幸的是,用于药物发现的细胞测定通常依赖于单层生长的单一细胞类型,而肿瘤生物学的这方面效果非常差。这可能是抗癌药物临床试验成功率低的因素之一。尽管可以在类组织环境中结合多种细胞类型的细胞模型,但它们很难与制药公司当前用于细胞功能高内涵分析的自动显微成像平台集成。一个特别具有挑战性的问题是检测细胞外基质中的可溶性旁分泌信号因子。尽管抗体可用于许多这些因素,但现有的免疫测定方法不适合在致密基质中使用。一个根本的限制是需要多种成分:一抗和二抗报告试剂。为了克服这一限制,我们建议开发一种分子内免疫测定法;即具有内置荧光报告基因的抗体。我们将通过将荧光示踪剂拴在柔性多肽接头上来实现这一目标,该接头与用硒代半胱氨酸残基工程化的 IgG 和 Fab 片段进行位点特异性修饰。一种经过充分表征的血管内皮生长因子(VEGF)单克隆抗体将被用作初始模型。将组装和测试一系列原型分子内免疫测定试剂,用于基于荧光的 VEGF 检测,以获得最佳结构。在第二阶段,分子内免疫测定将与 BellBrook 的新型微导管阵列平台 iuvo 相结合,从而能够在单个细胞分泌的可溶性因子水平上对旁分泌信号进行动态成像。
公共卫生相关性:
肿瘤发生的重要方面是由不同细胞类型之间的信号传导控制的,这些细胞类型位于致密基质中,为组织提供结构支持并参与信号传导。不幸的是,很难将这些信号事件纳入可用于测试潜在抗癌药物的体外测定中。为了克服这一限制,我们建议开发一种新型免疫测定方法,该方法允许使用现有的自动检测仪器探测组织样基质中的细胞间信号传导。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Robert G Lowery其他文献
Robert G Lowery的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Robert G Lowery', 18)}}的其他基金
Targeting a Human Acyltransferase for Broad-Spectrum Antivirals
靶向人类酰基转移酶的广谱抗病毒药物
- 批准号:
10223496 - 财政年份:2021
- 资助金额:
$ 25.09万 - 项目类别:
Discovery of cGAS Inhibitors for Interferon-Driven Autoimmune Diseases
发现用于治疗干扰素驱动的自身免疫性疾病的 cGAS 抑制剂
- 批准号:
10258171 - 财政年份:2019
- 资助金额:
$ 25.09万 - 项目类别:
Discovery of cGAS Inhibitors for Interferon-Driven Autoimmune Diseases
发现用于治疗干扰素驱动的自身免疫性疾病的 cGAS 抑制剂
- 批准号:
10349593 - 财政年份:2019
- 资助金额:
$ 25.09万 - 项目类别:
HTS Assays for Targeting the cGAS-STING Pathway in Autoimmune Diseases and Cancer
针对自身免疫性疾病和癌症中的 cGAS-STING 通路的 HTS 检测
- 批准号:
9347049 - 财政年份:2017
- 资助金额:
$ 25.09万 - 项目类别:
Riboswitch Based Methyltransferase HTS Assay for Epigenetic Drug Discovery
基于核糖开关的甲基转移酶 HTS 测定用于表观遗传药物发现
- 批准号:
9266793 - 财政年份:2014
- 资助金额:
$ 25.09万 - 项目类别:
Riboswitch Based Methyltransferase HTS Assay for Epigenetic Drug Discovery
基于核糖开关的甲基转移酶 HTS 测定用于表观遗传药物发现
- 批准号:
8646158 - 财政年份:2014
- 资助金额:
$ 25.09万 - 项目类别:
Riboswitch Based Methyltransferase HTS Assay for Epigenetic Drug Discovery
基于核糖开关的甲基转移酶 HTS 测定用于表观遗传药物发现
- 批准号:
9140743 - 财政年份:2014
- 资助金额:
$ 25.09万 - 项目类别:
High Throughput Assay for Detecting Protein Modifications in Cell Lysates
用于检测细胞裂解物中蛋白质修饰的高通量测定
- 批准号:
8124311 - 财政年份:2011
- 资助金额:
$ 25.09万 - 项目类别:
Screening Device for Differentiated Primary Cell Models of Airway Epithelia
气道上皮分化原代细胞模型筛选装置
- 批准号:
8315901 - 财政年份:2010
- 资助金额:
$ 25.09万 - 项目类别:
Screening Device for Differentiated Primary Cell Models of Airway Epithelia
气道上皮分化原代细胞模型筛选装置
- 批准号:
8515510 - 财政年份:2010
- 资助金额:
$ 25.09万 - 项目类别:
相似国自然基金
CD147分子促侵袭表位的确认及基于抗原抗体复合物结构的新型抗肿瘤多肽设计
- 批准号:
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
针对绿脓杆菌三型毒性分泌系统关键调控蛋白spuE的抗体开发及机理研究
- 批准号:31771006
- 批准年份:2017
- 资助金额:60.0 万元
- 项目类别:面上项目
抑制性受体TIGIT高亲和力抗体的结构基础
- 批准号:U1732109
- 批准年份:2017
- 资助金额:66.0 万元
- 项目类别:联合基金项目
人乳头瘤病毒样颗粒不同中和表位的特性与结构基础研究
- 批准号:81471934
- 批准年份:2014
- 资助金额:72.0 万元
- 项目类别:面上项目
优化氰基类拟除虫菊酯农药残留筛查免疫分析方法的基础研究
- 批准号:30771425
- 批准年份:2007
- 资助金额:32.0 万元
- 项目类别:面上项目
相似海外基金
Development of serologic test for early risk stratification of islet autoimmunity in genetically predisposed T1D individuals
开发用于遗传易感性 T1D 个体胰岛自身免疫早期风险分层的血清学检测
- 批准号:
10760885 - 财政年份:2023
- 资助金额:
$ 25.09万 - 项目类别:
First-in-human study of a potent anti-HBsAg neutralizing antibody
强效抗 HBsAg 中和抗体的首次人体研究
- 批准号:
10550458 - 财政年份:2023
- 资助金额:
$ 25.09万 - 项目类别:
Optimizing Syngeneic Mouse Models to Target Mutant p53
优化同基因小鼠模型以靶向突变 p53
- 批准号:
10677353 - 财政年份:2023
- 资助金额:
$ 25.09万 - 项目类别:
Developing a multi-component vaccine harnessing potent antibody and cellular responses against the blood-stage of Plasmodium falciparum
开发一种多成分疫苗,利用针对恶性疟原虫血液阶段的有效抗体和细胞反应
- 批准号:
10614511 - 财政年份:2022
- 资助金额:
$ 25.09万 - 项目类别:
Structure-guided engineering to increase respiratory syncytial virus G protein immunogenicity
结构引导工程提高呼吸道合胞病毒G蛋白免疫原性
- 批准号:
10521837 - 财政年份:2022
- 资助金额:
$ 25.09万 - 项目类别: